Hepatitis Monthly

Published by: Kowsar

Serum Lipoprotein Profiles and Response to Pegylated Interferon Plus Ribavirin Combination Therapy in Patients With Chronic HCV Genotype 1b Infection

Yoshio Aizawa 1 , * , Noritomo Shimada 2 , Hiroshi Abe 1 , Nobuyoshi Seki 1 , Yuta Aida 1 , Haruya Ishiguro 1 , Makiko Ika 2 , Keizo Kato 2 and Akihito Tsubota 3
Authors Information
1 Department of Gastroenterology and Hepatology, Jikei University School of Medicine, Tokyo, Japan
2 Department of Gastroenterology and Hepatology, Shinmatsudo Chuo General Hospital, Chiba, Japan
3 Institute of Clinical Medicine and Research, Jikei University Kashiwa Hospital, Chiba, Japan
Article information
  • Hepatitis Monthly: May 2013, 13 (5); e8988
  • Published Online: May 27, 2013
  • Article Type: Research Article
  • Received: November 6, 2012
  • Revised: March 7, 2013
  • Accepted: April 7, 2013
  • DOI: 10.5812/hepatmon.8988

To Cite: Aizawa Y, Shimada N, Abe H, Seki N, Aida Y, et al. Serum Lipoprotein Profiles and Response to Pegylated Interferon Plus Ribavirin Combination Therapy in Patients With Chronic HCV Genotype 1b Infection, Hepat Mon. 2013 ;13(5):e8988. doi: 10.5812/hepatmon.8988.

Copyright: Copyright © 2013, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Syed GH, Amako Y, Siddiqui A. Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol Metab. 2010; 21(1): 33-40[DOI][PubMed]
  • 2. Heaton NS, Randall G. Multifaceted roles for lipids in viral infection. Trends Microbiol. 2011; 19(7): 368-75[DOI][PubMed]
  • 3. Huang H, Sun F, Owen DM, Li W, Chen Y, Gale M, Jr., et al. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci U S A. 2007; 104(14): 5848-53[DOI][PubMed]
  • 4. Scholtes C, Ramiere C, Rainteau D, Perrin-Cocon L, Wolf C, Humbert L, et al. High plasma level of nucleocapsid-free envelope glycoprotein-positive lipoproteins in hepatitis C patients. Hepatology. 2012; 56(1): 39-48[DOI][PubMed]
  • 5. Nielsen SU, Bassendine MF, Burt AD, Martin C, Pumeechockchai W, Toms GL. Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J Virol. 2006; 80(5): 2418-28[DOI][PubMed]
  • 6. Burlone ME, Budkowska A. Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. J Gen Virol. 2009; 90: 1055-70[DOI][PubMed]
  • 7. Gopal K, Johnson TC, Gopal S, Walfish A, Bang CT, Suwandhi P, et al. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology. 2006; 44(2): 335-40[DOI][PubMed]
  • 8. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol. 2007; 46(3): 403-10[DOI][PubMed]
  • 9. Economou M, Milionis H, Filis S, Baltayiannis G, Christou L, Elisaf M, et al. Baseline cholesterol is associated with the response to antiviral therapy in chronic hepatitis C. J Gastroenterol Hepatol. 2008; 23(4): 586-91[DOI][PubMed]
  • 10. Hsu CS, Liu CH, Liu CJ, Wang CC, Chen CL, Lai MY, et al. Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection. Am J Gastroenterol. 2009; 104(3): 598-604[DOI][PubMed]
  • 11. Zampino R, Ingrosso D, Durante-Mangoni E, Capasso R, Tripodi MF, Restivo L, et al. Microsomal triglyceride transfer protein (MTP) -493G/T gene polymorphism contributes to fat liver accumulation in HCV genotype 3 infected patients. J Viral Hepat. 2008; 15(10): 740-6[DOI][PubMed]
  • 12. Sheridan DA, Price DA, Schmid ML, Toms GL, Donaldson P, Neely D, et al. Apolipoprotein B-associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti-viral agents interferon-alpha and ribavirin. Aliment Pharmacol Ther. 2009; 29(12): 1282-90[DOI][PubMed]
  • 13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18(6): 499-502[PubMed]
  • 14. Margolis J, Kenrick KG. Polyacrylamide gel electrophoresis in a continuous molecular sieve gradient. Anal Biochem. 1968; 25(1): 347-62[PubMed]
  • 15. Steim JM, Edner OJ, Bargoot FG. Structure of human serum lipoproteins: nuclear magnetic resonance supports a micellar model. Science. 1968; 162(3856): 909-11[PubMed]
  • 16. Usui S, Hara Y, Hosaki S, Okazaki M. A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. J Lipid Res. 2002; 43(5): 805-14[PubMed]
  • 17. Okazaki M, Usui S, Ishigami M, Sakai N, Nakamura T, Matsuzawa Y, et al. Identification of unique lipoprotein subclasses for visceral obesity by component analysis of cholesterol profile in high-performance liquid chromatography. Arterioscler Thromb Vasc Biol. 2005; 25(3): 578-84[DOI][PubMed]
  • 18. Van den Eynde E, Crespo M, Esteban JI, Jardi R, Ribera E, Carbonell J, et al. Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial. Clin Infect Dis. 2009; 48(8): 1152-9[DOI][PubMed]
  • 19. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009; 49(4): 1335-74[DOI][PubMed]
  • 20. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996; 24(2): 289-93[DOI][PubMed]
  • 21. Aizawa Y, Yohizawa K, Aida Y, Ishiguro H, Abe H, Tsubota A. Genotype rs8099917 near the IL28B gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum apolipoprotein B-100 concentration in chronic hepatitis C. Mol Cell Biochem. 2012; 360(1-2): 9-14[DOI][PubMed]
  • 22. Blaising J, Pecheur EI. Lipids: a key for hepatitis C virus entry and a potential target for antiviral strategies. Biochimie. 2013; 95(1): 96-102[DOI][PubMed]
  • 23. Sheridan DA, Neely RD, Bassendine MF. Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs). Clin Res Hepatol Gastroenterol. 2012;
  • 24. Aizawa Y, Abe H. Viral Factors Associated With Response to Antiviral Therapy for Chronic Hepatitis C Virus Infection. J Antivir Antiretrovir S. 2012; 3: 3
  • 25. Usui S, Mizuno T, Okazaki M, Nakamura M, Sakurabayashi I. Evaluation of a gel-permeation high-performance liquid chromatography for determining triglyceride levels in serum major lipoproteins, compared with the ultracentrifugation/precipitation method. Clin Biochem. 2009; 42(1-2): 114-7[DOI][PubMed]
  • 26. Ramcharran D, Wahed AS, Conjeevaram HS, Evans RW, Wang T, Belle SH, et al. Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology. 2010; 52(3): 854-63[DOI][PubMed]
  • 27. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461(7262): 399-401[DOI][PubMed]
  • 28. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009; 41(10): 1105-9[DOI][PubMed]
  • 29. Li JH, Lao XQ, Tillmann HL, Rowell J, Patel K, Thompson A, et al. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology. 2010; 51(6): 1904-11[DOI][PubMed]
  • 30. Clark PJ, Thompson AJ, Zhu M, Vock DM, Zhu Q, Ge D, et al. Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response. J Viral Hepat. 2012; 19(5): 332-40[DOI][PubMed]
  • 31. Mawatari H, Yoneda M, Fujita K, Nozaki Y, Shinohara Y, Sasaki H, et al. Association between lipoprotein subfraction profile and the response to hepatitis C treatment in Japanese patients with genotype 1b. J Viral Hepat. 2010; 17(4): 274-9[DOI][PubMed]
  • 32. Malmstrom R, Packard CJ, Caslake M, Bedford D, Stewart P, Yki-Jarvinen H, et al. Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects. Diabetes. 1998; 47(5): 779-87[PubMed]
  • 33. Perrin-Cocon L, Diaz O, Andre P, Lotteau V. Modified lipoproteins provide lipids that modulate dendritic cell immune function. Biochimie. 2013; 95(1): 103-8[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader